JBPHF (Jacobio Pharmaceuticals Group Co) Beta: 0.1364 (As of Jun. 27, 2026)


JBPHF Jacobio Pharmaceuticals Group Co Ltd JBPHF
54 GF Score
Price $0.87
GF Value $0.42
! 6 Warning Signs
View Full Analysis

What is Jacobio Pharmaceuticals Group Co Beta?

Jacobio Pharmaceuticals Group Co JBPHF +4.52% 54 Beta is 0.1364 as of Jun. 27, 2026. GuruFocus rates JBPHF with a GF Score™ of 54/100 and a GF Value™ of $0.42. The stock has 6 warning signs investors should review.

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-06-27), Jacobio Pharmaceuticals Group Co's Beta is 0.1364.


Jacobio Pharmaceuticals Group Co  (OTCPK:JBPHF) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


Jacobio Pharmaceuticals Group Co Beta Related Terms


Jacobio Pharmaceuticals Group Co Beta Historical Data

* Premium members only.

The historical data trend for Jacobio Pharmaceuticals Group Co's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Jacobio Pharmaceuticals Group Co Beta Chart

Jacobio Pharmaceuticals Group Co Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beta
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Jacobio Pharmaceuticals Group Co Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

JBPHF vs VRTX, REGN, ALNY: Beta Comparison

For the Biotechnology subindustry, Jacobio Pharmaceuticals Group Co's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Jacobio Pharmaceuticals Group Co Beta vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Jacobio Pharmaceuticals Group Co's Beta distribution charts can be found below:

* The bar in red indicates where Jacobio Pharmaceuticals Group Co's Beta falls into.


JBPHF
54GF Score
Jacobio Pharmaceuticals Group Co Ltd JBPHF
Beta is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Jacobio Pharmaceuticals Group Co Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Frequently Asked Questions Learn more about Beta →
What does a Beta of 0.1364 mean?
Jacobio Pharmaceuticals Group Co (JBPHF) has a Beta of 0.1364 as of Jun. 27, 2026. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Jacobio Pharmaceuticals Group Co and its competitors.
Is Jacobio Pharmaceuticals Group Co's Beta too high?
Jacobio Pharmaceuticals Group Co's current Beta is 0.1364. Overall, Jacobio Pharmaceuticals Group Co has a GF Score™ of 54/100, reflecting its overall financial health beyond just this single metric.
How does Jacobio Pharmaceuticals Group Co's Beta compare to VRTX and REGN?
Jacobio Pharmaceuticals Group Co's Beta of 0.1364 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beta for a Biotechnology company?
A good Beta depends on the Biotechnology industry context. However, Beta should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beta mean?
A high Beta can signal that a stock is expensive relative to its fundamentals. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Jacobio Pharmaceuticals Group Co and its competitors. Jacobio Pharmaceuticals Group Co's current Beta is 0.1364. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jacobio Pharmaceuticals Group Co stock overvalued right now?
Jacobio Pharmaceuticals Group Co (JBPHF) has a current Beta of 0.1364. The stock's GF Value™ is $0.42, compared to a current price of $0.87 — trading 106.6% above its estimated fair value. The current Beta is 0.1364. Jacobio Pharmaceuticals Group Co's overall GF Score™ is 54/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beta calculated?
Beta is calculated from a company's financial statements. For Jacobio Pharmaceuticals Group Co (JBPHF), the current Beta is 0.1364 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Jacobio Pharmaceuticals Group Co (JBPHF) Overvalued in 2026?

Based on GuruFocus' analysis, Jacobio Pharmaceuticals Group Co stock appears to be overvalued. The current stock price of $0.87 is trading 106.6% above its estimated GF Value™ of $0.42.

Key valuation signals for JBPHF:

  • Beta: 0.1364
  • GF Value™: $0.42 vs. price of $0.87 (106.6% above fair value)
  • GF Score™: 54/100 with 6 warning signs

No single metric tells the full story. See the JBPHF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Jacobio Pharmaceuticals Group Co Business Description

Other Exchanges 01167:Hong Kong77V:Germany
Address No.105 Jinghai 3rd Road, Building 8, Beijing Economic-Technological Development Area, Beijing, CHN
Jacobio Pharmaceuticals Group Co Ltd is a clinical-stage pharmaceutical company focusing on the in-house discovery and development of oncology therapies. The company is engaged in developing breakthrough cancer therapies for patients. The producst pipeline of the company includes KRAS G12C inhibitor, SHP2 inhibitor, Pan-KRAS inhibitor, KRAS G12D ADC JAB-BX600, Aurora Kinase A (AURKA) inhibitor, BET inhibitor, P53 Y220C mutant proteins, and others.
54GF Score

Get the complete analysis for JBPHF

Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.87
Price
$0.42
GF Value